News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Talha Badar: Ruxolitinib Combined with Dexamethasone for Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis in China
Talha Badar/X
Jul 18, 2025, 16:28

Talha Badar: Ruxolitinib Combined with Dexamethasone for Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis in China

Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X about recent paper by De Zhou et al., published in Blood.

“Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China.

The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”

Title: Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

Authors: De Zhou, Xianbo Huang, Lixia Zhu, Xuelian Hu, Xiudi Yang, Mixue Xie, Xin Huang, Fang Yu, Juying Wei, Liya Ma, Jingjing Zhu, Shuqi Zhao, Wanzhuo Xie, Hongyan Tong, Jie Jin, Xiujin Ye

Read The Full Article at Blood.

Talha Badar: Ruxolitinib Combined with Dexamethasone for Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis in China

More posts featuring Talha Badar.

De Zhou Fang Yu Hemophagocytic Lymphohistiocytosis Hongyan Tong Jie Jin Jingjing Zhu Juying Wei Lixia Zhu Liya Ma Mixue Xie Shuqi Zhao Talha Badar Wanzhuo Xie Xianbo Huang Xin Huang Xiudi Yang Xiujin Ye Xuelian Hu
Special Coverage
Blog
Jul 18, 2025, 16:28
Talha Badar: Ruxolitinib Combined with Dexamethasone for Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis in China
Insight
Jul 18, 2025, 16:23
Leon Kaulen: The First Comprehensive Characterization of TIAN Arising in CNS Lymphoma
Blog
Jul 18, 2025, 16:15
Al-Ola A Abdallah: How BMI Affects Outcomes After Allogeneic Hematopoietic Stem Cell Transplant for AL and MDS
Blog
Jul 18, 2025, 16:05
Guest Editing a Special Issue on Lung Cancer - Submit Your Work!
Blog
Jul 18, 2025, 16:03
Mohamed Emam Sobeih: Don’t Miss ICONC 2025 - Egypt Cancer Support Foundation’s First Annual Conference
Science
Jul 18, 2025, 15:59
Ilyas Sahin: The Role of CLDN18.2-targeting ADC in Refractory Advanced GEJ Cancer Patients
Blog
Jul 18, 2025, 15:57
Jill Feldman: Calling All Thoracic Oncology Leaders to Join Us at the 7th Annual EGFR Resisters Research Summit
Science
Jul 18, 2025, 15:51
Nancy Lin: Palazestrant Demonstrates More Than 7 Months mPFS in EMERALD-Eligible ER+ MBC Patients
Blog
Jul 18, 2025, 15:45
Sumanta Pal: Ruchi Agarwal Presented Her Work on International Kidney Cancer Trial Availability
Blog
Jul 18, 2025, 15:43
Belén Garijo: Did You Know The Word “mentor” Originates From Homer’s Epic Poem The Odyssey?
Blog
Jul 18, 2025, 15:36
Olivier Elemento: Great Pleasure to Host Dr. Parsa Mirhaji And Adil Ahmed at The Englander Institute for Precision Medicine
Blog
Jul 18, 2025, 15:32
Vincent Rajkumar: ODAC Votes Against Belantamab Risk-Benefit for Myeloma